Autosomal dominant tubulointerstitial kidney disease (ADTKD) comprises several genetically distinct disorders that commonly progress to kidney failure in mid-adulthood. One genetic cause, designated ADTKD-MUC1, results from a frameshift mutation in the MUC1 gene that creates a novel neoprotein called MUC1-fs. This aberrant protein accumulates in distal renal tubular cells and is implicated in disease pathogenesis. Despite its recognized pathogenic role, the cellular regulation and mechanisms by which MUC1-fs contributes to tubular injury are not well defined.
To study MUC1-fs in a patient-relevant context, the investigators established primary tubular epithelial cell cultures from urine samples obtained from multiple affected probands. These primary cells were subsequently immortalized to enable extended in vitro analyses. The use of cells derived from a patient’s urine provided a noninvasive source of renal tubular cells that retain disease-relevant molecular features, allowing examination of the mutant protein in the genetic background of individual patients.
The study applied long-range sequencing approaches to define the structure of the MUC1 alleles in each patient-derived cell line. This included precise determination of the length of the variable repeat region on both alleles and localization of the mutated repeat unit responsible for generating the frameshift and the MUC1-fs neoprotein. These sequence-level characterizations were performed for each proband-derived model to link genotype to the observed protein and cellular phenotypes.
Patient-derived tubular cells expressed readily detectable levels of the pathogenic MUC1-fs. Comparative analyses demonstrated that MUC1-fs exhibits a considerably longer half-life than wild-type mucin 1, indicating altered protein turnover as a feature of the mutant product. The increased stability of MUC1-fs likely contributes to its accumulation within distal tubular cells and may be central to downstream pathogenic processes in ADTKD-MUC1.
The investigators tested pharmacologic modulation of the secretory pathway using the compound BRD4780, which had previously been reported as putatively therapeutic for modulating MUC1-related pathology. Treatment with BRD4780 reduced levels of MUC1-fs across each patient-derived cell model in this study, demonstrating a reproducible effect on the pathogenic neoprotein in vitro.
However, the compound did not act selectively on the mutant protein. Wild-type mucin 1 levels were also affected, and transcriptional profiling revealed that numerous other pathways were modulated by BRD4780, indicating broader and rather unselective effects on cellular transcriptional programs. These observations highlight the need for careful assessment of off-target or pleiotropic effects when considering candidate therapeutics for ADTKD-MUC1.
The authors conclude that tubular cells derived from patient urine constitute a suitable and scalable model to analyze the pathogenic MUC1-fs protein in the individual patient context. Such models enable genotype-phenotype correlation at the protein level and support pharmacological testing of novel therapies in cells that carry the patient’s native MUC1 alleles. The approach facilitates individualized in vitro evaluation of candidate interventions and mechanistic studies of ADTKD-MUC1.
Data generated for the project have been deposited in the Gene Expression Omnibus (GEO) under accession number GSE306788. The work received ethical approval from the Ethics committee of Friedrich-Alexander University Erlangen-Nuremberg, Germany. The authors declared no competing interests. The article notes that all necessary patient consents and institutional approvals were obtained and that reporting guidelines were followed.
Note: This summary and rewrite are based solely on the content provided in the source article. Specific experimental details, quantitative results, and methodological parameters beyond those reported in the source were not provided in the text and therefore are not included here.